Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30708692 | 0.78 | APOBEC3A (0.61) | APOBEC3AAPOBEC3GAXLPDE10APIK3CG | |
| SCHEMBL1441278 | 0.75 | APOBEC3A (0.53) | APOBEC3AAPOBEC3GAXLPDE10APIK3CG | |
| SCHEMBL9792881 | 0.75 | APOBEC3A (0.53) | APOBEC3AAPOBEC3GAXLPDE10APIK3CG | |
| SCHEMBL2181213 | 0.75 | APOBEC3A (0.53) | APOBEC3AAPOBEC3GAXLPDE10APIK3CG | |
| SCHEMBL27823665 | 0.75 | APOBEC3A (0.53) | APOBEC3AAPOBEC3GAXLPDE10APIK3CG | |
| SCHEMBL5435763 | 0.75 | APOBEC3A (0.53) | APOBEC3AAPOBEC3GAXLPDE10APIK3CG | |
| SCHEMBL2340742 | 0.75 | APOBEC3A (0.58) | APOBEC3AAPOBEC3GAXLPDE10APIK3CG | |
| SCHEMBL21863369 | 0.75 | APOBEC3A (0.53) | APOBEC3AAPOBEC3GAXLPDE10APIK3CG | |
| SCHEMBL22018908 | 0.75 | APOBEC3A (0.53) | APOBEC3AAPOBEC3GAXLPDE10APIK3CG | |
| SCHEMBL18397083 | 0.75 | APOBEC3A (0.49) | APOBEC3AAPOBEC3GPDE10APIK3CGSMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| CN-120058708-A | Alkynyl alcohol derivative and medical application thereof | 中国药科大学 | 2025-05-30 | — | — | CN | disclosed |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| WO-2025007863-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-09 | — | — | WO | disclosed |
| CN-119241532-A | 1H-pyrazolo [4,3-c ] pyridine compound, composition and application thereof | 深圳市塔吉瑞生物医药有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4436955-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| US-20230167068-A1 | BENZOPYRAZOLE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230167068-A1 | BENZOPYRAZOLE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| US-20210214373-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | Turning Point Therapeutics, Inc. | 2021-07-15 | — | — | US | disclosed |
| WO-2021136429-A1 | BENZOPYRAZOLE COMPOUND | 南京明德新药研发有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-20200347050-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-1922321-A1 | PYRAZOLOÝ1,5-A¨PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Eirx Therapeutics Ltd (IE) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007017678-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EIRX THERAPEUTICS LIMITED (IE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167068-A1 | BENZOPYRAZOLE COMPOUND | ABCB1, CYP3A43, CYP3A5 | APOBEC3A 3291/4885APOBEC3G 3281/4885AXL 4387/4885 |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | APOBEC3A 4520/4885APOBEC3G 4560/4885AXL 4063/4885 |
| US-20210214373-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | CSF3R, CSF1R, FLT3 | APOBEC3A 3993/4885APOBEC3G 4188/4885AXL 75/4885 |
| US-20200347050-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | SSB, TLR8, TLR9 | APOBEC3A 4685/4885APOBEC3G 4560/4885AXL 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.